HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

490.383

-13.015-2.59%

Number of Gainers:6

Number of Losers:23

Number of Flat:4

PE:- -

High:505.901

Open:503.516

Low:489.571

Close:503.398

Volume:82.72M

Turnover:2.69B

Market Cap:313.43B

Float Cap:277.25B

Loading ...

Ascentage Pharma Posts Interim Results Presentation on 1H 2026 Business Update

US Treasury Steps In to Calm Markets, Ending Wall Street's Three-Day Slide, While Moderna's Cancer Vaccine Breakthrough Sends Shares Soaring 176%

GENFLEET-B Advances Two First-in-Class Pancreatic Cancer Combination Therapies into Phase II Trials

Ascentage Pharma Reports 2026 Interim Results: Strengthening Commercial Engine and Accelerating Global Expansion

Ascentage Pharma Group International Posts H1 Net Loss Attributable Rmb816.7 Million

China's Ascentage Pharma H1 Revenue Rises 29% on Lisaftoclax Ramp-up

Ascentage Pharma Group International H1 Revenue RMB 302.2 Million

THOMSON REUTERS

Ascentage Pharma FY26 H1 Loss Widens to Us$120.4 Million; Revenue Rises 29% to Us$44.5 Million

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

THOMSON REUTERS

Evening Market Wrap: Cancer Vaccine Breakthrough Sends US Pharma Soaring, SK Hynix Announces Massive Buyback

Kintor Pharma-B Reports Interim Results with Narrowed Net Loss of RMB 75.6 Million

Kintor Net Loss Narrows 9% to RMB 75.8 Million in 1H FY26; Revenue Rises to RMB 52 Million

Kintor Pharmaceutical H1 Revenue RMB 52 Million

THOMSON REUTERS

Global First mRNA Cancer Vaccine Hits Major Milestone, 3D Medicines Jumps 17% on International Revaluation

Akeso (SEHK:9926) Could Be 47% Undervalued As China Approves Ivonescimab Use

Simply Wall St.

KEYMED BIO-B (02162) Announces Proposed RMB Share Issuance for STAR Market Listing

Keymed Biosciences Plans RMB Share Listing on Shanghai STAR Market

KeyMed Biosciences - no Application Made to Regulatory Authorities for RMB Share Issue as of Aug 19, 2026

THOMSON REUTERS

KeyMed Biosciences - Proposes RMB Share Issue for Sci-Tech Board Listing

THOMSON REUTERS

KeyMed Biosciences H1 Revenue RMB 617.068 Million

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/BK1574/news?page=18"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":490.383,"timestamp":1788250091886,"preClose":503.39795,"halted":0,"volume":82724645,"delay":0,"changeRate":-0.025854,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-13.014954,"latestTime":"09-01 16:00:00","open":503.51608,"high":505.9005,"low":489.5706,"amount":2688849767,"amplitude":0.032439,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788312600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"pbRate":3.790203,"peRate":127.340212,"turnoverRate":0.003099,"increases":6,"decrements":23,"flats":3,"marketCap":313429262448,"floatMarketCap":277247178824},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":505.9005,"amplitude":0.032439,"preClose":503.39795,"low":489.5706,"pbRate":"3.790203","latestPrice":490.383,"volume":82724645,"delay":0,"open":503.51608,"prevYearClose":556.26263,"prevWeekClose":523.873,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":512.773,"twentyDayClose":475.248,"sixtyDayClose":459.637,"secType":"PLATE","market":"HK","turnoverRate":0.003099,"peRate":127.340212,"marketCap":313429262448,"floatMarketCap":277247178824,"timestamp":1788250091886,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":23,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:18,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660753474","title":"Ascentage Pharma Posts Interim Results Presentation on 1H 2026 Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2660753474","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660753474?lang=en_us&edition=fundamental","pubTime":"2026-08-20 09:16","pubTimestamp":1787188598,"startTime":"0","endTime":"0","summary":"Ascentage Pharma posts interim results presentation on 1H 2026 business updateAscentage reported 1H 2026 revenue of USD 44.5 million, up 29% year over year; product sales totaled USD 41.6 million.Cash","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL44PrT2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146381026","title":"US Treasury Steps In to Calm Markets, Ending Wall Street's Three-Day Slide, While Moderna's Cancer Vaccine Breakthrough Sends Shares Soaring 176%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146381026","media":"Stock News","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146381026?lang=en_us&edition=fundamental","pubTime":"2026-08-20 09:10","pubTimestamp":1787188237,"startTime":"0","endTime":"0","summary":"Market Open Briefing1. US Treasury intervention steadies markets; Moderna surges 176%US stocks snapped a three-session losing streak after the Treasury Department moved to address bond market...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK4585","IDNA","BK4548","BK4568","09939","BK4588","BK1574","GNOM","BK4501","BK4551","LGHT","WDNA","399300","02827","83188","03130","BK1161","159982","83130","BK4532","MRNX","MRNY","BK1147","MRNA","07233","BK4534","03188","BK4139","BK1515","BK4533","02846","82846"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193023804","title":"GENFLEET-B Advances Two First-in-Class Pancreatic Cancer Combination Therapies into Phase II Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1193023804","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193023804?lang=en_us&edition=fundamental","pubTime":"2026-08-20 08:16","pubTimestamp":1787184978,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) has announced the initiation of a three-arm, parallel-controlled Phase II clinical study evaluating GFH375, an oral KRAS G12D ON/OFF inhibitor. The trial will assess two novel...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1515","09939","02595","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199487193","title":"Ascentage Pharma Reports 2026 Interim Results: Strengthening Commercial Engine and Accelerating Global Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1199487193","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199487193?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:40","pubTimestamp":1787182818,"startTime":"0","endTime":"0","summary":"Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) has announced its interim results for the first half of 2026, showcasing continued momentum in its commercial operations. Total revenue for the period...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AAPG","06855","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660116479","title":"Ascentage Pharma Group International Posts H1 Net Loss Attributable Rmb816.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660116479","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660116479?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:29","pubTimestamp":1787182190,"startTime":"0","endTime":"0","summary":"BRIEF-Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 MillionAug 20 (Reuters) - Ascentage Pharma Group International H1 revenue RMB 302.2 millionH1 net income attributable RMB -816.7 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nPLXJC7R3Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06855","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660479671","title":"China's Ascentage Pharma H1 Revenue Rises 29% on Lisaftoclax Ramp-up","url":"https://stock-news.laohu8.com/highlight/detail?id=2660479671","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660479671?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:17","pubTimestamp":1787181459,"startTime":"0","endTime":"0","summary":"China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-upOverviewChina oncology drug developer's H1 revenue rose 29% yr/yr on higher product salesNet loss widened as operating expenses and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL1N44G15G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1574","BK1589","LU1064131003.USD","BK1161","IE00BZ08YR35.GBP","06990","LU2148510915.USD","002422","IE00BZ08YT58.USD","LU1064130708.USD","BK1521","BK0060","LU1979443071.USD","BK0239","BK1515","LU1934453819.USD","BK1191","01177","IE00BZ08YS42.EUR","LU0196878994.USD","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660479392","title":"Ascentage Pharma Group International H1 Revenue RMB 302.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660479392","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660479392?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:00","pubTimestamp":1787180455,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nPLXJC7R3Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660313479","title":"Ascentage Pharma FY26 H1 Loss Widens to Us$120.4 Million; Revenue Rises 29% to Us$44.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660313479","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660313479?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:00","pubTimestamp":1787180428,"startTime":"0","endTime":"0","summary":"Ascentage Pharma FY26 H1 loss widens to US$120.4 million; revenue rises 29% to US$44.5 millionAscentage Pharma revenue rose 29% year over year to US$ 44.5 million for the six months ended June 30, 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL6yrd94:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","BK1574","BK4112","BK4585","BK1161","SG9999014039.USD","06855","SG9999014005.SGD","LU2095319765.USD","BK4588","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","NDAQ","LU2210150020.SGD","LU2210149790.SGD","LU0314104364.USD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","BCDF","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660793944","title":"Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2660793944","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660793944?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:00","pubTimestamp":1787180400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA4ML19T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170810384","title":"Evening Market Wrap: Cancer Vaccine Breakthrough Sends US Pharma Soaring, SK Hynix Announces Massive Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=1170810384","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170810384?lang=en_us&edition=fundamental","pubTime":"2026-08-19 22:40","pubTimestamp":1787150452,"startTime":"0","endTime":"0","summary":"Here are the key evening market developments investors need to know. NDRC Advances 'Six Networks' Infrastructure Plan On August 19, the National Development and Reform Commission (NDRC) held a...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03188","07233","BK1574","83188","83130","03130","BK1147","159938","09939","159646","BK1161","399300","BK1515","02827","82846","02846","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178952366","title":"Kintor Pharma-B Reports Interim Results with Narrowed Net Loss of RMB 75.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1178952366","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178952366?lang=en_us&edition=fundamental","pubTime":"2026-08-19 22:40","pubTimestamp":1787150416,"startTime":"0","endTime":"0","summary":"Kintor Pharma-B (09939) has unveiled its interim financial results for the period ending June 30, 2026, showcasing a notable surge in revenue from RMB 6 million in the prior-year period to RMB 52...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660242429","title":"Kintor Net Loss Narrows 9% to RMB 75.8 Million in 1H FY26; Revenue Rises to RMB 52 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660242429","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660242429?lang=en_us&edition=fundamental","pubTime":"2026-08-19 22:33","pubTimestamp":1787149999,"startTime":"0","endTime":"0","summary":"Kintor net loss narrows 9% to RMB 75.8 million in 1H FY26; revenue rises to RMB 52 millionKintor posted revenue of RMB 52 million, up 766.7% year over year, driven by global sales of its KOSHIN cosmet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL7xt97N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660429211","title":"Kintor Pharmaceutical H1 Revenue RMB 52 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660429211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660429211?lang=en_us&edition=fundamental","pubTime":"2026-08-19 22:32","pubTimestamp":1787149978,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nPLXXDMDQT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09939","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150133670","title":"Global First mRNA Cancer Vaccine Hits Major Milestone, 3D Medicines Jumps 17% on International Revaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=1150133670","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150133670?lang=en_us&edition=fundamental","pubTime":"2026-08-19 22:22","pubTimestamp":1787149350,"startTime":"0","endTime":"0","summary":"On August 19, a landmark moment arrived for tumor immunotherapy. Moderna and Merck announced that their phase III clinical trial, INTerpath-001, evaluating the tumor neoantigen mRNA vaccine mRNA-4157...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1574","01244","159938","BK1515","BK1161","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660244894","title":"Akeso (SEHK:9926) Could Be 47% Undervalued As China Approves Ivonescimab Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2660244894","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660244894?lang=en_us&edition=fundamental","pubTime":"2026-08-19 22:20","pubTimestamp":1787149244,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) is back in focus after China’s National Medical Products Administration approved ivonescimab plus chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer.\nSee our latest analysis for Akeso.\nDespite the positive ivonescimab news, Akeso’s share price has come under pressure, with the stock down 12.54% over the past week and 21.18% year to date. At the same time, the 3 year total shareholder return of 185.76% and 5 year total shareholder return...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-could-be-47-undervalued-as-china-approves-ivo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-could-be-47-undervalued-as-china-approves-ivo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348767384.USD","LU0348766576.USD","BK1161","LU0540923850.HKD","LU2488822045.USD","LU2778985437.USD","IE00B5MMRT66.SGD","LU1961090484.USD","BK1574","LU0417516738.SGD","LU0561508036.HKD","LU2476274308.USD","LU2399975544.HKD","LU0348735423.USD","LU1720050803.USD","LU0417516571.SGD","LU0634319403.HKD","KURE","LU0348784397.USD","LU0417516902.SGD","IE00B543WZ88.USD","LU0348783233.USD","LU1794554557.SGD","IE00BPRC5H50.USD","LU0348825331.USD","09926","LU0348827113.USD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189925275","title":"KEYMED BIO-B (02162) Announces Proposed RMB Share Issuance for STAR Market Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=1189925275","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189925275?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:40","pubTimestamp":1787146814,"startTime":"0","endTime":"0","summary":"KEYMED BIO-B (02162) has announced that its board of directors resolved on August 19, 2026, to propose the issuance of ordinary shares denominated and traded in Renminbi, with a planned listing on...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UCmain","MCNHmain","BK1161","KSTR","BK1583","BK1587","MUCmain","BK1574","IPOS","02162","CNHmain","CYB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660425003","title":"Keymed Biosciences Plans RMB Share Listing on Shanghai STAR Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2660425003","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660425003?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:32","pubTimestamp":1787146323,"startTime":"0","endTime":"0","summary":"Keymed Biosciences plans RMB share listing on Shanghai STAR MarketKeymed Biosciences’ board on Aug. 19, 2026 backed a plan to issue RMB-denominated ordinary shares for listing on Shanghai’s Sci-Tech B","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL75lXNG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","02162","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660425012","title":"KeyMed Biosciences - no Application Made to Regulatory Authorities for RMB Share Issue as of Aug 19, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660425012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660425012?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:31","pubTimestamp":1787146294,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nFWN44G0G8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1587","02162","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660250934","title":"KeyMed Biosciences - Proposes RMB Share Issue for Sci-Tech Board Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2660250934","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660250934?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:31","pubTimestamp":1787146294,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nFWN44G0G8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1583","02162","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660425459","title":"KeyMed Biosciences H1 Revenue RMB 617.068 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660425459","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660425459?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:23","pubTimestamp":1787145836,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nPLXHNXCKZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","02162","BK1161","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":19,"pageCount":18,"totalSize":379,"code":"91000000","status":"200"}]}}